WCA
SRPT icon

Westover Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Westover Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,625
Closed -$319K – 246
2024
Q4 		$319K Hold
2,625
– – 0.07% 186
2024
Q3 		$328K Hold
2,625
– – 0.06% 193
2024
Q2 		$415K Buy
+2,625
New +$337K 0.11% 148

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Westover Capital Advisors's SRPT Position: Q1 2025 in Review

Westover Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,625 shares — an estimated $319K sold.

Westover Capital Advisors first reported a position in SRPT in Q2 2024 and held it in 3 quarters. The position peaked at $415K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Westover Capital Advisors reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Westover Capital Advisors sold 2,625 Sarepta Therapeutics shares in Q1 2025, an estimated $319K.
  • Westover Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 3 quarters.
  • Westover Capital Advisors's Sarepta Therapeutics position peaked at $415K in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Westover Capital Advisors's 13F filing for Q1 2025, filed 6 May 2025.